Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
 LLY | Eli Lilly & Co. | $1.0t | $1158.85 | +1.5% | 1.6M |
 RVMD | Revolution Medicines, Inc. Common Stock | $44.3b | $200.70 | -3.7% | 1.5M |
 INCY | Incyte Genomics Inc | $23.4b | $114.28 | -1.2% | 2.1M |
 JAZZ | Jazz Pharmaceuticals, Inc. | $15.3b | $231.52 | -1.9% | 674.4K |
 EXEL | Exelixis Inc | $14.5b | $58.11 | -0.9% | 1.6M |
 CORT | Corcept Therapeutics Inc. | $12.6b | $120.08 | -2.0% | 595.9K |
 HALO | Halozyme Therapeutics, Inc. | $12.5b | $109.11 | +1.3% | 1.5M |
 NUVL | Nuvalent, Inc. Class A Common Stock | $9.8b | $123.96 | 0.0% | N/A |
 COGT | Cogent Biosciences, Inc. Common Stock | $5.4b | $30.45 | -1.7% | 2.0M |
 ERAS | Erasca, Inc. Common Stock | $5.2b | $14.44 | -2.8% | 4.3M |
 RLAY | Relay Therapeutics, Inc. Common Stock | $4.2b | $18.60 | -3.3% | 3.2M |
 TNGX | Tango Therapeutics, Inc. | $3.9b | $21.81 | -5.2% | 4.0M |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $3.6b | $36.63 | -3.8% | 649.8K |
 CELC | Celcuity Inc. Common Stock | $3.5b | $71.76 | -3.1% | 1.3M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | $3.4b | $43.17 | -6.7% | 1.6M |
 NRIX | Nurix Therapeutics, Inc. Common stock | $2.4b | $22.66 | -1.3% | 851.1K |
 IMNM | Immunome, Inc. | $2.4b | $19.57 | -8.8% | 2.2M |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.52 | -0.0% | 3.0M |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $2.0b | $42.48 | -3.2% | 653.3K |
 BHVN | Biohaven Ltd. | $1.9b | $12.18 | -6.9% | 2.5M |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.9b | $11.70 | -1.5% | 2.2M |
 NUVB | Nuvation Bio Inc. | $1.8b | $4.92 | -1.4% | 5.9M |
 ZYME | Zymeworks Inc. | $1.8b | $25.57 | -2.0% | 471.4K |
 NVCR | NovoCure Limited Ordinary Shares | $1.7b | $15.12 | -1.6% | 1.3M |
 TYRA | Tyra Biosciences, Inc. Common Stock | $1.4b | $20.71 | -3.5% | 640.4K |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $1.4b | $14.96 | -46.9% | 19.3M |
 DMRA | Damora Therapeutics, Inc. Ordinary Shares | $1.3b | $19.17 | -3.3% | 1.1M |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $1.3b | $11.78 | -4.2% | 1.9M |
 KURA | Kura Oncology, Inc. | $0.9b | $10.58 | -0.8% | 1.0M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $0.9b | $9.97 | -3.8% | 805.9K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.9b | $46.62 | -2.9% | 164.7K |
 GERN | Geron Corp | $0.8b | $1.22 | -0.4% | 5.0M |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $0.7b | $7.92 | -4.1% | 879.6K |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $0.7b | $20.66 | -6.2% | 147.4K |
 VSTM | Verastem, Inc. | $0.7b | $7.96 | -3.0% | 2.3M |
 DCTH | Delcath Systems Inc | $0.5b | $15.43 | -2.8% | 206.4K |
 MNPR | Monopar Therapeutics Inc. Common Stock | $0.5b | $79.95 | +2.3% | 289.0K |
 PBYI | PUMA BIOTECHNOLOGY INC | $490.9m | $9.51 | -1.7% | 203.9K |
 ARVN | Arvinas, Inc | $484.5m | $7.32 | -1.9% | 447.0K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $384.0m | $3.27 | -5.9% | 1.6M |
 CCCC | C4 Therapeutics, Inc. | $362.9m | $2.88 | -3.3% | 1.9M |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $311.9m | $3.56 | -3.2% | 573.5K |
 PRLD | Prelude Therapeutics Incorporated | $292.9m | $3.81 | +1.1% | 339.2K |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $266.0m | $4.16 | -2.3% | 131.4K |
 IMRX | Immuneering Corporation Class A Common Stock | $263.3m | $3.85 | -5.0% | 848.7K |
 STRO | Sutro Biopharma, Inc. | $254.5m | $14.45 | -4.5% | 144.0K |
 ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | $238.6m | $2.70 | -4.3% | 770.0K |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $210.9m | $3.62 | -2.4% | 439.6K |
 PYXS | Pyxis Oncology, Inc. Common Stock | $178.5m | $2.06 | -9.8% | 1.4M |
 ASRT | Assertio Holdings, Inc. Common Stock | $151.5m | $23.49 | 0.0% | N/A |